The utilization of appropriate osteoporosis medications improves following a multifaceted educational intervention: the Canadian quality circle project (CQC)

Table 2 The use of appropriate therapy in the High risk, Low risk and Low risk without fractures group at baseline, Follow-up #1 and Follow-up #2*

	Baseline % (n)	Follow-up #1 % (n)	Final follow-up % (n)
Appropriate therapy
High risk group	34.7 (1040/2996)	40.1 (1243/3098)	41.2 (735/1784)
Low risk group	81.9 (2874/3506)	83.4 (2052/2460)	84.3 (782/928)
Low risk group without fractures	83.4 (2778/3332)	86.1 (1956/2272)	86.5 (763/882)

* The high risk group was defined as patients with osteopenia and prior fragility fracture, osteopenia and at least one other major (excluding prior fracture) or two minor risk factors for future fracture, or osteoporosis defined as a bone mineral density t-score of less than -2.5 regardless of risk factor status. The low risk group was defined as patients with osteopenia and no prior fracture, osteopenia and at most one minor risk factor for fracture, have normal or no bone mineral density measurements regardless of risk factor status (guidelines). The low risk no fracture group was defined as patients with osteopenia and no prior fracture, osteopenia and at most one minor risk factor for fracture, have normal or no bone mineral density measurements without a prior fracture. Appropriate therapy was defined as any treatment (including alendronate, calcitonin, etidronate, hormone replacement therapy, PTH, raloxifene, or risedronate) administered to high risk patients and no treatment administered to low risk patients.

ISSN: 1472-6920